Recalcitrant Folliculitis Decalvans Treatment Outcomes With Biologics and Small Molecule Inhibitors.

IF 2.1 4区医学 Q3 DERMATOLOGY

Cutis Pub Date : 2024-05-01 DOI:10.12788/cutis.1023

Tamara Fakhoury, Katelyn Urban, Leila Ettefagh, Navid Nami

引用次数: 0

Abstract

Folliculitis decalvans (FD) is a rare primary neutrophilic cicatricial alopecia that commonly displays resistance to traditional therapies and remains challenging to treat. Currently, data are lacking with recommendations for therapy-recalcitrant FD. A systematic review was conducted to analyze biologics, small molecule inhibitors, tumor necrosis factor (TNF) inhibitors, Janus kinase (JAK) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and monoclonal antibodies utilized in the treatment of recalcitrant FD.

查看原文本刊更多论文

使用生物制剂和小分子抑制剂治疗 Decalvans 顽固性毛囊炎的疗效。

德加尔旺毛囊炎（FD）是一种罕见的原发性嗜中性卡他性脱发，通常会对传统疗法产生抗药性，治疗起来仍具有挑战性。目前，尚缺乏针对蜕皮性脱发的治疗建议数据。我们进行了一项系统性综述，分析了用于治疗顽固性脱发的生物制剂、小分子抑制剂、肿瘤坏死因子（TNF）抑制剂、Janus 激酶（JAK）抑制剂、磷酸二酯酶 4（PDE4）抑制剂和单克隆抗体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cutis 医学-皮肤病学

CiteScore

1.10

自引率

0.00%

发文量

191

审稿时长

6-12 weeks

期刊介绍： Published since 1965, Cutis is a peer-reviewed clinical journal for the dermatologist, allergist, and general practitioner. The journal is published monthly and focuses on concise clinical articles that present the practical side of dermatology. Referenced in Index Medicus/MEDLINE, it is respected and enjoyed by both specialists and derm-active generalists, enabling its readers to get what they need quickly and efficiently. Furthermore, Cutis is read by more physicians actively involved in the day-to-day treatment of dermatologic conditions than any other dermatology publication. Covering a broad range of pertinent and timely topics, Cutis is written and edited by industry leaders. For information on article submissions, please see our Information for Authors.